Stay updated on Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added. The government funding lapse notice and the older Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedA new site-wide notice about government funding status was added and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary visibility was added and study record metadata updated (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0). Older labels were tweaked or removed (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4) To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedA minor template/version update was applied: Revision v3.3.4 replacing v3.3.3, with no changes to study content or page functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedA dedicated Locations section was added, listing Washington as a study location. The HHS Vulnerability Disclosure link and the standalone Washington Locations entry were removed, and the revision updated to v3.3.3.SummaryDifference0.2%

- Check85 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2. No substantive study information appears to change.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.